Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing
Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Antonio Calles(Dana-Farber Cancer Institute), Íñigo Martínez(Hospital Universitario Ramón y Cajal), Victoria Tirado(Hospital General Universitario Gregorio Marañón), Rosa Álvarez(Hospital General Universitario Gregorio Marañón), Mar Galera(Hospital General Universitario Gregorio Marañón), M.A. Arregui(Hospital General Universitario Gregorio Marañón), Inmaculada Aparicio(Hospital General Universitario Gregorio Marañón)
Cited by 4
Related Papers
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
|The Lancet Neurology|2012|553
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
|Journal of Thoracic Oncology|2015|290
Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease
|JAMA Neurology|2015|131
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
|Clinical Cancer Research|2018|125
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
|British Journal of Cancer|2022|112